References
- F. Bazgir, J. Nau, S. Nakhaei-Rad, E. Amin, M. J. Wolf, J. J. Saucerman, K. Lorenz and M. R. Ahmadian, The microenvironment of the pathogenesis of cardiac hypertrophy, Cells 12 (2023) Article ID 1780 (35 pages); https://doi.org/10.3390/cells12131780
- Y. Bei, Y. Zhu, M. Wei, M. Yin, L. Li, C. Chen, Z. Huang, X. Liang, J. Gao, J. Yao, P. H. van der Kraak, A. Vink, Z. Lei, Y. Dai, H. Chen, Y. Liang, J. PG Sluijter and J. Xiao, HIPK1 inhibition protects against pathological cardiac hypertrophy by inhibiting the CREB-C/EBPβ axis, Adv. Sci. 10(18) (2023) e2300585 (15 pages); https://doi.org/10.1002/advs.202300585
- G. Chen, N. An, J. Shen, H. Chen, Y. Chen, J. Sun, Z. Hu, J. Qiu, C. Jin, S. He, L. Mei, Y. Sui, W. Li, P. Chen, X. Guan, M. Chu, Y. Wang, L. Jin, K. Kim, X. Li, W. Cong and X. Wang, Fibroblast growth factor 18 alleviates stress-induced pathological cardiac hypertrophy in male mice, Nat. Commun. 14 (2023) Article ID 1235 (18 pages); https://doi.org/10.1038/s41467-023-36895-1
- L. Zhou, M. Li, Z. Chai, J. Zhang, K. Cao, L. Deng, Y. Liu, C. Jiao, G.-M. Zou, J. Wu and F. Han, Anticancer effects and mechanisms of astragaloside IV, Oncol. Rep. 49 (2023) Article ID 5 (15 pages); https://doi.org/10.3892/or.2022.8442
- E. M. Boorsma, J. M. ter Maaten, K. Damman, W. Dinh, F. Gustafsson, S. Goldsmith, D. Burkhoff, F. Zannad, J. E. Udelson and A. A. Voors, Congestion in heart failure: A contemporary look at physiology, diagnosis and treatment, Nat. Rev. Cardiol. 10 (2020) 641–655; https://doi.org/10.1038/s41569-020-0379-7
- V. Castiglione, A. Aimo, G. Vergaro, L. Saccaro, C. Passino and M. Emdin, Biomarkers for the diagnosis and management of heart failure, Heart Fail. Rev. 2 (2022) 625–643; https://doi.org/10.1007/s10741-021-10105-w
- C. Bonvicini, S. V. Faraone and C. Scassellati, Attention-deficit hyperactivity disorder in adults: A systematic review and meta-analysis of genetic, pharmacogenetic and biochemical studies, Mol. Psychiatry 21 (2016) 872–884; https://doi.org/10.1038/mp.2016.74
- M. G. Crespo-Leiro and E. Barge-Caballero, Advanced heart failure: Definition, epidemiology, and clinical course, Heart Fail. Clin. 17(4) (2021) 533–545; https://doi.org/10.1016/j.hfc.2021.06.002
- E. La Franca, G. Manno, L. Ajello, G. Di Gesaro, C. Minà, C. Visconti, D. Bellavia, C. Falletta, G. Romano, S. Dell’ Oglio, P. Licata, A. Caronia, M. Gallo and F. Clemenza, Physiopathology and diagnosis of congestive heart failure: Consolidated certainties and new perspectives, Curr. Probl. Cardiol. 46(3) (2021) Article ID 100691 (16 pages); https://doi.org/10.1016/j.cpcardiol.2020.100691
- Y. Gao, X. Su, T. Xue and N. Zhang, The beneficial effects of astragaloside IV on ameliorating diabetic kidney disease, Biomed. Pharmacother. 163 (2023) Article ID 114598 (12 pages); https://doi.org/10.1016/j.biopha.2023.114598
- X. Chen, T. Yang, Y. Zhou, Z. Mei and W. Zhang; Astragaloside IV combined with ligustrazine ameliorates abnormal mitochondrial dynamics via Drp1 SUMO/deSUMOylation in cerebral ische mia-reperfusion injury, CNS Neurosci. Ther. 30(4) (2024) e14725 (18 pages); https://doi.org/10.1111/cns.14725
- Y. Liang, B. Chen, D. Liang, X. Quan, R. Gu, Z. Meng, H. Gan, Z. Wu, Y. Sun, S. Liu and G. Dou, Pharmacological effects of astragaloside IV: A review, Molecules 28(16) (2023) Article ID 166118 (16 pages); https://doi.org/10.3390/molecules28166118
- J. Wan, Z. Zhang, C. Wu, S. Tian, Y. Zang, G. Jin, Q. Sun, P. Wang, X. Luan, Y. Yang, X. Zhan, L. L. Ye, D. D. Duan, X. Liu and W. Zhang, Astragaloside IV derivative HHQ16 ameliorates infarction--induced hypertrophy and heart failure through degradation of lncRNA4012/9456, Sig. Transduct. Target Ther. 8 (2023) Article ID 414 (16 pages); https://doi.org/10.1038/s41392-023-01660-9
- J. Wang, X. Pu, H. Zhuang, Z. Guo, M. Wang, H. Yang, C. Li and X. Chang, Astragaloside IV alleviates septic myocardial injury through DUSP1-prohibitin 2 mediated mitochondrial quality control and ER-autophagy, J. Adv. Res. 75 (2025) 561–580; https://doi.org/10.1016/j.jare.2024.10.030
- P. Umapathi, O. O. Mesubi, P. S. Banerjee, N. Abrol, Q. Wang, E. D. Luczak, Y. Wu, J. M. Granger, A.-C. Wei, O. E. Reyes Gaido, L. Florea, C. Conover Talbot, G. W. Hart, N. E. Zachara and M. E. Anderson, Excessive O-GlcNAcylation causes heart failure and sudden death, Circulation 143(17) (2021) 1687–1703; https://doi.org/10.1161/CIRCULATIONAHA.120.051911
- Z. Feng, L. Pan, C. Qiao, Y. Yang, X. Yang and Y. Xie, Cardamonin intervenes in myocardial hypertrophy progression by regulating Usp18, Phytomedicine 134 (2024) Article ID 155970 (12 pages); https://doi.org/10.1016/j.phymed.2024.155970
- E. Dai, X. Guo, J. Wang, Q. Hu, J. Li, Q. Tang, H. Zu, H. Huan, Y. Wang, Y. Gao, G. Hu, W. Li, Z. Liu, Q. Ma, Y. Song, J. Yang, Y. Zhu, S. Huang, Z. Meng, B. Bai, Y. Chen, C. Gao, M. Huang, S. Jin, M. Lu, Z. Xu, Q. Zhang, S. Zheng, Q. Zeng and X. Qi, Investigate of the etiology and prevention status of liver cirrhosis, Zhonghua Yi Xue Za Zhi, 12 (2023) 913–919; https://doi.org/10.3760/cma.j.cn112137-20221017-02164
- S. Kaul, A. Embaby, K. M. Heinhuis, N. S. IJzerman, A. M. Koenen, S. van der Kleij, I. Hofland, H. van Boven, J. Sanders, W. T. A. van der Graaf, R. L. Haas, A. D. R. Huitema, W. J. van Houdt and N. Steeghs, Propranolol monotherapy in angiosarcoma – A window-of-opportunity study (PropAngio), Eur. J. Cancer 202 (2024) Article ID 113974 (7 pages); https://doi.org/10.1016/j.ejca.2024.113974
- D. E. Le, N. J. Alkayed, Z. Cao, N. N. Chattergoon, M. Garcia-Jaramillo, K. Thornburg and S. Kaul, Metabolomics of repetitive myocardial stunning in chronic multivessel coronary artery stenosis: Effect of non-selective and selective β1-receptor blockers, J. Physiol. 602(14) (2024) 3423–3448; https://doi.org/10.1113/JP285720
- X. Wang, Y. Wang, D. Huang, S. Shi, P. Caixia, Y. Wu, S. Zherui, F. Wang, Z. Wang, Astragaloside IV regulates the ferroptosis signaling pathway via the Nrf2/SLC7A11/GPX4 axis to inhibit PM2.5- mediated lung injury in mice, Int. Immunopharmacol. 112 (2022) Article ID 109186 (12 pages); https://doi.org/10.1016/j.intimp.2022.109186
- K. Okabayashi, Y. Wakao and T. Narita, Release of secretory immunoglobulin A by submandibular gland via β adrenergic receptor stimulation, Arch. Oral Biol. 129 (2021) Article ID 105209 (5 pages); https://doi.org/10.1016/j.archoralbio.2021.105209
- Y. Q. Tan, H. W. Chen and J. Li, Astragaloside IV: An effective drug for the treatment of cardiovascular diseases, Drug Des. Devel. Ther. 14 (2020) 3731–3746; https://doi.org/10.2147/DDDT.S272355
- W. Tian, P. Zhang, L. Yang, P. Song, J. Zhao, H. Wang, Y. Zhao and L. Cao, Astragaloside IV alleviates doxorubicin-induced cardiotoxicity by inhibiting cardiomyocyte pyroptosis through the SIRT1/NLRP3 pathway, Am. J. Chin. Med. 52(2) (2024) 453–469; https://doi.org/10.1142/S0192415X24500198
- Y. Su, X. Yin, X. Huang, Q. Guo, M. Ma, L. Guo, Astragaloside IV ameliorates sepsis-induced myocardial dysfunction by regulating NOX4/JNK/BAX pathway, Life Sci. 310 (2022) Article ID 121123 (10 pages); https://doi.org/10.1016/j.lfs.2022.121123